Synonyms: 5-(2-Amino-1-(4-morpholinophenyl)-1H-benzimidazol-6-yl)-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide; 5-(2-Amino-1-(4-morpholinophenyl)-1H-benzo[d]imidazol-6-yl)-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide; 5-[2-Amino-1-[4-(4-morpholinyl)phenyl]-1H-benzimidazol-6-yl]-N-(2-fluorophenyl)-2-methoxy-3-pyridinesulfonamide; Compound A1; PI4KA Inhibitor A1
Molecular Formula: C29H27FN6O4S
Molecular Weight: 574.63
Linear Structural Formula: C29H27FN6O4S
MDL Number: MFCD29770784
Purity: >=98% (HPLC)
Storage: -20C
Biochem Physiol Actions: GSK-A1 is an ATP site-targeting, highly potent and selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIalpha) inhibitor (pIC50 = 8.5-9.8) that selectively downregulates cellular PtdIns(4)P, but not PtdIns(4,5)P2, level (HEK293 IC50 = 3 nM, complete depletion of HEK293 & COS-7 plasma membrane PtdIns(4)P by 100 nM post 10 min treatment) with much reduced potency toward PI4KB (pIC50 = 7.2-7.7), PI3KA/B/D/G (pIC50 = 7.3/7/7.1/7.8) or PI4K/2A/2B (pIC50<5 ). gsk-a1 is a useful tool for probing pi4ka-dependent cellular processes and viral replication (typical culture treatment conc. range: 10-100 nm).<>